Paysign stock dropped 12.3% despite beating Q1 earnings expectations with 50.8% revenue growth and 80% EPS growth. The decline was triggered by management's decision to maintain prior guidance rather than raise it, disappointing investors after the stock had already rallied 35% year-to-date. At 23.5x forward earnings with nearly 100% projected earnings growth, analysts suggest the stock may be attractive at current levels, though small-cap risks remain.

Paysign (NASDAQ: PAYS) reported strong Q1 2026 results with 51% revenue growth to $28.04 million, driven by 82% pharma revenue growth and 25% plasma revenue growth. Net income nearly doubled to $5.44 million ($0.09 per share), with adjusted EBITDA up 113% to $10.59 million. The company added 45 net patient affordability programs (135 total) and 89 plasma centers (573 total), exceeding guidance across all metrics.

Paysign stock surged 35.8% on March 25, 2026, following strong Q4 earnings that beat sales expectations at $22.76M versus $21.55M forecast. The company projects 2026 revenue between $106.5M-$110.5M (32.5% growth) with net income of $13M-$16M, driven by momentum in pharmaceuticals and plasma verticals. Despite today's rally, the stock remains down roughly 1% year-to-date.

Motley Fool analysts discuss two lesser-known stocks that could become much larger businesses in the future, offering opportunities beyond popular household names for investors willing to look beyond mainstream investments.

Paysign reported strong Q2 2025 earnings with 33.1% revenue growth, driven by robust pharma patient affordability programs, despite softening plasma revenue. The company raised its full-year guidance and showed significant profitability improvements.

PaySign (NASDAQ:PAYS) underwent analysis by 7 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 3 4 0 0 0 Last 30D 0 1 0 0 0 1M Ago 0 0 0 0 0 2M Ago 2 3 0 0 0 3M Ago 1 0 0 0 0 Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $6.07, along with a high estimate of $7.00 and a low estimate of $4.50. This current average has increased by 8.98% from the previous average price target of $5.57. Understanding Analyst Ratings: A Comprehensive Breakdown The analysis of recent analyst actions sheds light on the perception of PaySign by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Gary Prestopino Barrington Research Maintains Outperform $7.00 $7.00 Gary Prestopino Barrington Research Maintains Outperform $7.00 $7.00 Gary Prestopino Barrington Research Raises Outperform $7.00 $5.50 Michael Diana Maxim Group Raises Buy $6.00 $5.50 Gary Prestopino Barrington Research Maintains Outperform $5.50 $5.50 Peter Heckmann DA Davidson Raises Buy $5.50 $4.50 Peter Heckmann DA Davidson Raises Buy $4.50 $4.00 Key Insights: Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to ...Full story available on Benzinga.com

In the last three months, 9 analysts have published ratings on PaySign (NASDAQ:PAYS), offering a diverse range of perspectives from bullish to bearish. The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 4 5 0 0 0 Last 30D 0 1 0 0 0 1M Ago 2 2 0 0 0 2M Ago 1 0 0 0 0 3M Ago 1 2 0 0 0 Analysts have set 12-month price targets for PaySign, revealing an average target of $5.61, a high estimate of $7.00, and a low estimate of $4.00. This current average reflects an increase of 10.87% from the previous average price target of $5.06. Interpreting Analyst Ratings: A Closer Look An in-depth analysis of recent analyst actions unveils how financial experts perceive PaySign. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Gary Prestopino Barrington Research Maintains Outperform $7.00 $7.00 Gary Prestopino Barrington Research Raises Outperform $7.00 $5.50 Michael Diana Maxim Group Raises Buy $6.00 $5.50 Gary Prestopino Barrington Research Maintains Outperform $5.50 $5.50 Peter Heckmann DA Davidson Raises Buy $5.50 $4.50 Peter Heckmann DA Davidson Raises Buy $4.50 $4.00 Gary Prestopino Barrington Research Maintains Outperform $5.50 $5.50 Peter Heckmann DA Davidson Raises Buy $4.00 $3.00 Gary Prestopino Barrington Research Maintains Outperform $5.50 - Key Insights: Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to ...Full story available on Benzinga.com

In the preceding three months, 5 analysts have released ratings for PaySign (NASDAQ:PAYS), presenting a wide array of perspectives from bullish to bearish. The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 3 2 0 0 0 Last 30D 1 0 0 0 0 1M Ago 1 0 0 0 0 2M Ago 1 2 0 0 0 3M Ago 0 0 0 0 0 The 12-month price targets, analyzed by analysts, offer insights with an average target of $5.0, a high estimate of $5.50, and a low estimate of $4.00. This current average has increased by 17.65% from the previous average price target of $4.25. Exploring Analyst Ratings: An In-Depth Overview A comprehensive examination of how financial experts perceive PaySign is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Peter Heckmann DA Davidson Raises Buy $5.50 $4.50 Peter Heckmann DA Davidson Raises Buy $4.50 $4.00 Gary Prestopino Barrington Research Maintains Outperform $5.50 $5.50 Peter Heckmann DA Davidson Raises Buy $4.00 $3.00 Gary Prestopino Barrington Research Maintains Outperform $5.50 - Key Insights: Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' ...Full story available on Benzinga.com

U.S. stocks traded mostly higher toward the end of trading, with the Dow Jones index gaining over 300 points on Wednesday. The Dow traded up 0.78% to 39,589.55 while the NASDAQ fell 0.02% to 16,312.74. The S&P 500 also rose, gaining, 0.36% to 5,222.18. Check This Out: Top 3 Energy Stocks That May Keep You Up At Night In Q1   Leading and Lagging Sectors   Utilities shares jumped by 2% on Wednesday. In trading on Wednesday, communication services shares fell by 0.5%.   Top Headline   Cintas Corporation (NASDAQ: CTAS) reported better-than-expected third-quarter financial results and raised FY24 guidance. Cintas posted GAAP earnings of $3.84 per share, beating market estimates of $3.59 per share. The company’s quarterly sales came in at $2.406 billion, versus expectations of $2.386 billion, according to data from Benzinga Pro. Cintas increased FY24 annual revenue expectations from $9.48 billion-$9.56 billion to $9.57 billion-$9.60 billion (estimate: $9.56 billion). The firm raised EPS outlook from $14.35-$14.65 to $14.80-$15.00 (estimate: $14.60).   Equities Trading UP   Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT) shares shot up 44% to $3.2571 after the company announced the publication of pre-clinical data on its lead clinical ...

Shares of LuxUrban Hotels Inc. (NASDAQ: LUXH) fell sharply during Wednesday’s session after the company issued preliminary fourth-quarter revenue outlook below estimates. LuxUrban said it expects preliminary revenue of $28.2 million for the fourth quarter, versus market estimates of $34.199 million, according to data from Benzinga Pro. LuxUrban Hotels shares dipped 27.4% to $1.5523 on Wednesday. Here are some other stocks moving in today's mid-day session. Gainers MariaDB plc (NYSE: MRDB) climbed 70.4% to $0.3850 after Progress Software announced that it is possibly considering an offer for the company. Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT) shares jumped 68.6% to $3.8099 after the company announced the publication of pre-clinical data on its lead clinical compound, LB-100. Nutriband Inc. (NASDAQ: NTRB) gained 33.2% to $3.9950 after the company provided a clinical and regulatory path overview for its AVERSA Fentanyl patch. Verb Technology Company, Inc. (NASDAQ: VERB) surged 30.5% to $0.3656 after the company announced that its MARKET.live entered into a formal partnership with TikTok to become a service provider for TikTok Shop and will receive a TikTok Shop Partner designation. PaySign, Inc. (NASDAQ: PAYS) gained 28.2% to $4.3299 after the company announced better-than-expected fourth-quarter results. Destiny Tech100 Inc (NASDAQ: DXYZ) rose 26.6% to $11.39 after gaining 9% on Tuesday. PAVmed Inc. (NASDAQ: PAVM) gained 19.7% to $2.4798 after the company issued business update and fourth quarter financial results. Noah Holdings Limited (NYSE: NOAH) rose 17.5% to $11.89 after the company reported fourth quarter financial results. NuScale Power Corporation (NYSE: SMR) rose 17.5% to $4.89. The ONE Group Hospitality, Inc. (NASDAQ: STKS) shares rose 17.2% to $4.70 after the company announced that it will ...

U.S. stocks traded mostly higher midway through trading, with the Dow Jones gaining over 200 points on Wednesday. The Dow traded up 0.56% to 39,502.25 while the NASDAQ fell 0.08% to 16,302.03. The S&P 500 also rose, gaining, 0.27% to 5,217.52. Check This Out: Top 3 Energy Stocks That May Keep You Up At Night In Q1   Leading and Lagging Sectors   Real estate shares jumped by 1.8% on Wednesday. In trading on Wednesday, information technology shares fell by 0.4%.   Top Headline   Crude oil inventories in the U.S. increased by 3.165 million barrels in the week ended March 22, compared to market estimates of a 1.275 million decline, the Energy Information Administration said.   Equities Trading UP   Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT) shares shot up 49% to $3.38 after the company announced the publication of pre-clinical data on its lead clinical compound, LB-100. Shares of MariaDB plc (NYSE: MRDB) got a boost, surging 73% to $0.39 after Progress Software announced that it is possibly considering an offer for the company. PaySign, Inc. ...

U.S. stocks were higher, with the Dow Jones index gaining around 300 points on Wednesday. Shares of Cintas Corporation (NASDAQ: CTAS) rose sharply during Wednesday’s session after the company reported better-than-expected third-quarter financial results and raised FY24 guidance. Cintas posted GAAP earnings of $3.84 per share, beating market estimates of $3.59 per share. The company’s quarterly sales came in at $2.406 billion, versus expectations of $2.386 billion, according to data from Benzinga Pro. Cintas shares climbed 9.7% to $694.62 on Wednesday. Here are some other big stocks recording gains in today’s session. PaySign, Inc. (NASDAQ: PAYS) shares jumped 28.2% to $4.3299 after the company announced better-than-expected fourth-quarter results. Noah Holdings Limited (NYSE: NOAH) climbed 17.5% to $11.89 ...